Roche: Roche Q1 sales up 7% on drugs Phesgo, Vabysmo

FRANKFURT (Reuters) -Swiss drugmaker Roche said on Thursday its first-quarter sales rose a forecast-beating 7% driven by breast cancer drug Phesgo, eye drug Vabysmo and allergy treatment Xolair. Quarterly group revenues came in at 15.44 billion Swiss francs ($18.64 billion), slightly above average market expectations of about 15.4 billion cited by analysts. Roche said it was still targeting an increase in full-year adjusted earnings per share at a high single-digit percentage. (Reporting by Ludwig Burger, Editing by Rachel More) FRANKFURT (Reuters) -Swiss drugmaker Roche said on Thursday its first-quarter sales rose a forecast-beating 7% driven by breast cancer drug Phesgo, eye drug Vabysmo and allergy treatment Xolair. Quarterly group revenues came in at 15.44 billion Swiss francs ($18.64 billion), slightly above average market expectations of about 15.4 billion cited by analysts. Roche said it was still targeting an increase in full-year adjusted earnings per share at a high single-digit percentage. (Reporting by Ludwig Burger, Editing by Rachel More)